Meeting
2018 ASCO Annual Meeting
The use of exosome and immune profiling to analyze a phase 2 study on the addition of patritumab or placebo to cetuximab and a platinum agent for recurrent / metastatic head and neck cancer (R/M HNSCC) patients.
Authors
Tony Ng
King's College London, London, United Kingdom
Tony Ng , Fabian Flores-Borja , Giovanna Alfano , Paul Barber , Gregory Weitsman , Felix Wong , Jose Vicencio , Myria Galazi , Jana Doyle , Jonathan Greenberg , Martin David Forster , Anthonius Coolen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT02633800
Citation
J Clin Oncol 36, 2018 (suppl; abstr 6043)
DOI
10.1200/JCO.2018.36.15_suppl.6043
Abstract #
6043
Poster Bd #
31
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Randomized phase 2 trial of patritumab (P) or placebo (PBO) + cetuximab (C) + cisplatin (CIS) or carboplatin (CAR) for recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
First Author: Kevin J. Harrington
Poster
2016 ASCO Annual Meeting
Patritumab (P) or placebo (PBO) plus cetuximab (C) and platinum-based therapy in squamous cell carcinoma of the head and neck (SCCHN): a phase 2 study.
First Author: Kevin J. Harrington
Poster
2016 ASCO Annual Meeting
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
First Author: Makoto Tahara
Poster
2012 ASCO Annual Meeting
Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: The ADVANTAGE phase II trial.
First Author: Jan Baptist Vermorken